Eli Lilly announced that it will cap the out-of-pocket cost of its insulin at $35 a month, putting the drugmaker in line with a provision in the Inflation Reduction Act. This change takes effect immediately and could prompt other insulin makers in the U.S. to follow suit. Insulin makers have faced pressure from members of Congress and advocacy groups to lower the cost of the lifesaving medication, and President Biden has called on other drugmakers to also lower insulin prices.
Photo Credit: Dima Solomin
Comments